Henrik Ørum

Chief Scientific Officer @ CiVi Biopharma, Inc.

About

More than 20 years as a senior biotech executive, with extensive experience in every aspect of creating, leading and succesfully exiting companies in the fields of in-vitro diagnostics and antisense therapeutics. PhD in molecular Biology. 70+ peer reviewed publications and books; countless scientific and business presentations at international conferences and symposiums. Involved in the start up/founder of 4 biotech companies: - PNA Diagnostics - a Diagnostics company that was sold to Boehringer Mannheim in 2004, - Exiqon A/S - a diagnostic company listed on the Copenhagen Stock Exchange (EXQ), - Santaris Pharma A/S- a biotherapeutic company that was sold to Hoffmann La Roche in 2014, - CiVi Biopharma Inc. - a biotherapeutic company that was founded in 2016. Broad strategical/operational experiences in: - Managing and capitalizing early and mid-stage Biotech companies, integrating and running companies post acquisition by big pharma. - Negotiating high value company acquisitions/drug discovery/drug development deals with big pharmaceutical and biotech companies. - Establishing, managing and motivating innovative, hard working R & D organisations in the fields of in-vitro diagnostice and antisense therapeutics. - Developing strong technology platforms, and discovering & clinically developing antisense drugs in the fields of cancer, rare genetic disorders, infectious and metabolic diseases. - Establishing and leading high-performance business development departments, responsible for opportunity identification and evaluation, negotiating in/out-licensing deals, market & competitive analyses, strategic planning and corporate profiling. Raised more than 300M $ from US and European venture capital and institutional investors in multiple rounds of investments. Broad experience in creating shareholder value through spin-out, merger, trade sale and IPO.

Country

Denmark

City

Copenhagen

Industry

Pharmaceuticals

Skill

Biotechnology, Molecular Biology, Drug Discovery, Drug Development, Clinical Trials, Pharmaceutical Industry, Clinical Development, Oncology, R, Life Sciences, Biopharmaceuticals, Biochemistry, Cancer, Infectious Diseases, Technology Transfer, Business Development

Experience

Chief Scientific Officer

CiVi Biopharma, Inc.

2016 - Present · 10 yrs

Washington DC/Philadelphia

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi's innovative pipeline includes CIVI 007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of cardiovascular disease. In addition the Company currently has other clinical stage development program activity aimed at treating severe liver and vascular diseases.

Head of RNA Therapeutic Research, Roche pRED & Gen.Man. of Roche Innovation Center Copenhagen

Roche

2014 - 2016 · 2 yrs

Copenhagen/Basel

CSO and VP Bussiness Development

Santaris Pharma A/S

2000 - 2014 · 14 yrs

Copenhagen/San Diego

Santaris Pharma is a privately owned, clinical-stage biopharmaceutical company focused on developing a novel class of antisense drugs, termed LNA, intended to safely and effectively switch off harmful genes in a variety of diseases. The company was founded in 2003 through the merger of two smaller Danish biotech companies (Cureon A/S, founded in 2000 and Pantheco A/S founded in 1998) both of which focused on antisense drug development. Santaris owns the LNA (Locked Nucleic Acid) chemistry & drug discovery platform and is leveraging it through a combination of in-house drug discovery & development programmes and through R & D partnerships with pharmaceutical companies, which currently include Pfizer, Enzon, GSK, Wyeth, Shire and Miragen. The company and its pharmaceutical partners have six drugs in the clinic and several in late pre-clinical testing, addressing unmet medical needs in cancer, metabolic disorders, infectious diseases and rare genetic disorders. The lead drug is being developed for the treatment of viral hepatitis C infections and has successfully completed a phase II 4-week monotherapy study in treatment naïve patients chronically infected with HCV genotype 1.

Vice-Chairman of the board

Exiqon A/S

1995 - 2002 · 7 yrs

Exiqon is a diagnostic company listed on the Copenhagen stock exchange (EXQ). The company focuses on developing innovative new products and services for basic research and molecular diagnostics. The company has built an extensive product line including state-of-the-art products for miRNA expression profiling and detection, mRNA-PCR amplification, in-situ hybridisation and mRNA isolation. The company is located in Hørsholm Denmark.

CSO

PNA Diagnostics

1993 - 1999 · 6 yrs

Copenhagen/Penzberg

PNA Diagnostics was a Danish biotech company, based on a world-wide exclusive license to use the PNA (Peptide Nucleic Acid) chemistry in diagnostics and monitoring. The company was established in 1992, as a venture backed company, with the objective to build a broad, new platform with freedom-to-operate in the field of human in-vitro diagnostics. The company was sold to Boehringer Mannheim in August 1994 and changed ownership to Hoffman la Roche in 1997 as part of their acquisition of Boehringer Mannheim. In 1999, PNA diagnostics was sold to DAKO, DK.